Distinguished in Lung Adenocarcinoma

Dr. Giuseppe Giaccone

Hematology Oncology | Oncology | Hematology
New York Queens Medicine And Surgery, P.C.
5634 Main St, Fl 1, 
Flushing, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Distinguished in Lung Adenocarcinoma
New York Queens Medicine And Surgery, P.C.
5634 Main St, Fl 1, 
Flushing, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Giuseppe Giaccone is a Hematologist Oncology specialist and an Oncologist in Flushing, New York. Dr. Giaccone is rated as a Distinguished provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Thymic Epithelial Tumor, Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Tissue Biopsy.

His clinical research consists of co-authoring 253 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles in the study of Lung Adenocarcinoma.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Specialist in MD
Hospital Affiliations
New York-Presbyterian/queens
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

NEW YORK QUEENS MEDICINE AND SURGERY, P.C.
5634 Main St, Fl 1, Flushing, NY 11355
Other Locations
NEW YORK QUEENS MEDICINE AND SURGERY, P.C.
1402 150th St, Apt 1, Whitestone, NY 11357
NEW YORK QUEENS MEDICINE AND SURGERY, P.C.
16303 Horace Harding Expy, Fresh Meadows, NY 11365

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma
Enrollment Status: Recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: VMD-928
Study Phase: Phase 1
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Enrollment Status: Completed
Publish Date: March 25, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Paclitaxel, Ramucirumab
Study Phase: Phase 2
Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations
Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations
Enrollment Status: Terminated
Publish Date: July 05, 2024
Intervention Type: Drug
Study Drugs: Dasatinib, Osimertinib
Study Phase: Phase 1/Phase 2
Phase II Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors
Phase II Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors
Enrollment Status: Terminated
Publish Date: April 16, 2024
Intervention Type: Drug
Study Drug: KN046
Study Phase: Phase 2
A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT)
A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT)
Enrollment Status: Terminated
Publish Date: February 16, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
Phase I/II Trial of Anti-PD-1 Checkpoint Inhibitor Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
Phase I/II Trial of Anti-PD-1 Checkpoint Inhibitor Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: March 16, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 1/Phase 2
Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas
Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas
Enrollment Status: Unknown
Publish Date: December 13, 2019
Intervention Type: Drug
Study Drugs: Pembrolizumab, Epacadostat
Study Phase: Phase 2
View 9 Less Clinical Trials

253 Total Publications

A novel phenotype of sporadic Creutzfeldt-Jakob disease.
A novel phenotype of sporadic Creutzfeldt-Jakob disease.
Journal: BMJ case reports
Published: August 09, 2025
Similar Doctors
Elite in Lung Adenocarcinoma
Dr. Charles M. Rudin
Hematology Oncology | Oncology
Elite in Lung Adenocarcinoma
Dr. Charles M. Rudin
Hematology Oncology | Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (6.9 miles away)
212-639-2131
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Charles Rudin is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Rudin is rated as an Elite provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), and Tissue Biopsy. Dr. Rudin is currently accepting new patients.

Elite in Lung Adenocarcinoma
Dr. Mark G. Kris
Oncology
Elite in Lung Adenocarcinoma
Dr. Mark G. Kris
Oncology

Memorial Solid Tumor Group

353 E 68th St, 
New York, NY 
 (7.0 miles away)
646-422-4300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Kris is an Oncologist in New York, New York. Dr. Kris is rated as an Elite provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Lung Adenocarcinoma, Lung Cancer, EGFR Positive Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC).

Gregory J. Riely
Elite in Lung Adenocarcinoma
Dr. Gregory J. Riely
Oncology
Elite in Lung Adenocarcinoma
Dr. Gregory J. Riely
Oncology

Memorial Solid Tumor Group

530 E 74th St, 
New York, NY 
 (6.7 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gregory Riely is an Oncologist in New York, New York. Dr. Riely is rated as an Elite provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Lung Cancer, Lung Adenocarcinoma, Thymic Epithelial Tumor, Tissue Biopsy, and Liver Embolization. Dr. Riely is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Giaccone's expertise for a condition
ConditionClose
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile